These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 33142833)

  • 1. Sialorrhea in Parkinson's Disease.
    Isaacson J; Patel S; Torres-Yaghi Y; Pagán F
    Toxins (Basel); 2020 Oct; 12(11):. PubMed ID: 33142833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Saliva changes in Parkinson's disease patients after injection of Botulinum neurotoxin type A.
    Tiigimäe-Saar J; Tamme T; Rosenthal M; Kadastik-Eerme L; Taba P
    Neurol Sci; 2018 May; 39(5):871-877. PubMed ID: 29460161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Debilitating consequences of drooling.
    Bloem BR; Kalf JG; van de Kerkhof PC; Zwarts MJ
    J Neurol; 2009 Aug; 256(8):1382-3. PubMed ID: 19412723
    [No Abstract]   [Full Text] [Related]  

  • 4. Botulinum toxin for treatment of parkinsonian sialorrhea.
    Friedman A; Potulska A
    Neurol Neurochir Pol; 2001; 35 Suppl 3():23-7. PubMed ID: 12001650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sialorrhea in Parkinson's disease: a review.
    Chou KL; Evatt M; Hinson V; Kompoliti K
    Mov Disord; 2007 Dec; 22(16):2306-13. PubMed ID: 17659637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of severe drooling with botulinum toxin in amyotrophic lateral sclerosis and Parkinson's disease: efficacy and possible mechanisms.
    Møller E; Karlsborg M; Bardow A; Lykkeaa J; Nissen FH; Bakke M
    Acta Odontol Scand; 2011 May; 69(3):151-7. PubMed ID: 21198339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sialorrhea in patients with Parkinson's disease: safety and administration of botulinum neurotoxin.
    Egevad G; Petkova VY; Vilholm OJ
    J Parkinsons Dis; 2014; 4(3):321-6. PubMed ID: 24919823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Botulinum toxin A as treatment for drooling saliva in PD.
    Pal PK; Calne DB; Calne S; Tsui JK
    Neurology; 2000 Jan; 54(1):244-7. PubMed ID: 10636161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Botulinum Toxin A and B in sialorrhea: Long-term data and literature overview.
    Petracca M; Guidubaldi A; Ricciardi L; Ialongo T; Del Grande A; Mulas D; Di Stasio E; Bentivoglio AR
    Toxicon; 2015 Dec; 107(Pt A):129-40. PubMed ID: 26327120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BoNT clinical trial update: Sialorrhea.
    Tamadonfar ET; Lew MF
    Toxicon; 2023 Apr; 226():107087. PubMed ID: 36931440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-lasting benefits of botulinum toxin type B in Parkinson's disease-related drooling.
    Lagalla G; Millevolte M; Capecci M; Provinciali L; Ceravolo MG
    J Neurol; 2009 Apr; 256(4):563-7. PubMed ID: 19401804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson's disease.
    Ondo WG; Hunter C; Moore W
    Neurology; 2004 Jan; 62(1):37-40. PubMed ID: 14718694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Botulinum toxin B as an effective and safe treatment for neuroleptic-induced sialorrhea.
    Steinlechner S; Klein C; Moser A; Lencer R; Hagenah J
    Psychopharmacology (Berl); 2010 Jan; 207(4):593-7. PubMed ID: 19823807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of the pharmacological treatments for sialorrhea in patients with Parkinson's disease: a systematic review and network meta-analysis.
    Santos Junior LC; Santos JR; Reis A; Faria-E-Silva AL; Leal PC
    Clin Oral Investig; 2023 Jun; 27(6):2449-2463. PubMed ID: 37036514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The option of sonographic guidance in Botulinum toxin injection for drooling in Parkinson's disease.
    Jost WH
    J Neural Transm (Vienna); 2016 Jan; 123(1):51-5. PubMed ID: 26138438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Botulinum toxin type-B improves sialorrhea and quality of life in bulbaronset amyotrophic lateral sclerosis.
    Costa J; Rocha ML; Ferreira J; Evangelista T; Coelho M; de Carvalho M
    J Neurol; 2008 Apr; 255(4):545-50. PubMed ID: 18283399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of botulinum toxin type B for treatment of sialorrhea in Parkinson's disease: a prospective double-blind trial.
    Chinnapongse R; Gullo K; Nemeth P; Zhang Y; Griggs L
    Mov Disord; 2012 Feb; 27(2):219-26. PubMed ID: 21887710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism.
    Mancini F; Zangaglia R; Cristina S; Sommaruga MG; Martignoni E; Nappi G; Pacchetti C
    Mov Disord; 2003 Jun; 18(6):685-8. PubMed ID: 12784273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Botulinum toxin type A for control of drooling in Asian patients with cerebral palsy.
    Lin YC; Shieh JY; Cheng ML; Yang PY
    Neurology; 2008 Jan; 70(4):316-8. PubMed ID: 18209205
    [No Abstract]   [Full Text] [Related]  

  • 20. Drooling in Parkinson's disease: A randomized controlled trial of incobotulinum toxin A and meta-analysis of Botulinum toxins.
    Narayanaswami P; Geisbush T; Tarulli A; Raynor E; Gautam S; Tarsy D; Gronseth G
    Parkinsonism Relat Disord; 2016 Sep; 30():73-7. PubMed ID: 27406786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.